MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$2,030,765
Net loss
-$1,980,398
Series b convertible
preferred stock 8...
-$50,367
Interest income
$4,430
Loss from operations
-$1,801,354
Unrealized gain (loss) on
digital assets
-$182,887
Interest expense
$457
Realized gain (loss) on
foreign currency...
-$130
Total costs and
expenses
$1,801,354
General and
administrative costs
$1,750,658
Research and development
costs
$50,696
Back
Back
Income Statement
source: myfinsight.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)